Earlier this year, we looked at a privately held biotech called Jounce Therapeutics. At the time (Mid July) the company had struck a deal with Celgene Corporation (NASDAQ: CELG ), which could be worth up to $2.6 billion longer term, and was immediately worth $225 million by way of an upfront payment, and a further $36 million equity investment.